Hello, everyone, and welcome to the middle of the week, which arrived quickly, yes? A hazy, muggy morning is unfolding here on the Pharmalot campus, where the officials mascot is noisily snoozing and the short people are on their way to their various destinations. As for us, we are downing yet another needed cup of stimulation. Feel free to join us, as always. And here are some tidbits to help you along. Have a wonderful day and keep in touch …

The Trump administration announced a formal but preliminary plan to allow Americans to import certain lower-cost drugs from other countries, STAT reports. The plan puts most of the onus on state governments, which would have to come up with a proposal for safe importation and submit it for federal approval. This is the latest example of the Trump administration pursuing populist ideas for lowering prescription drugs — ideas that have traditionally been unpopular with drug makers and a large swath of the Republican Party.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy